Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 54 points (0.4%) at 15,287 as of Friday, May 17, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 1,992 issues advancing vs. 899 declining with 140 unchanged. The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Abbott Laboratories ( ABT), down 1.30, HCA Holdings ( HCA), down 1.19 and Stryker Corporation ( SYK), down 0.70. Top gainers within the industry include Humana ( HUM), up 2.3%, UnitedHealth Group ( UNH), up 1.6%, Express Scripts ( ESRX), up 1.3%, WellPoint ( WLP), up 1.2% and Intuitive Surgical ( ISRG), up 1.0%. TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today: 4. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry lower today. As of noon trading, Smith & Nephew is down $0.93 (-1.6%) to $58.85 on light volume Thus far, 14,425 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 72,900 shares. The stock has ranged in price between $58.83-$59.13 after having opened the day at $58.85 as compared to the previous trading day's close of $59.78. Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $10.8 billion and is part of the health care sector. The company has a P/E ratio of 16.0, below the S&P 500 P/E ratio of 17.7. Shares are up 7.9% year to date as of the close of trading on Thursday. TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Smith & Nephew Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.